Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 12/20 | 0.78 |
| ▸ | CHEK2 | O96017 | 7/20 | 0.61 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.61 |
| ▸ | ATR | Q13535 | 1/20 | 0.55 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.54 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.54 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.54 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.54 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30521741 | 0.87 | FYN (1.00) | FYNCHEK2CHEK1BMPR1ATGFBR1 | |
| SCHEMBL18613271 | 0.87 | FYN (1.00) | FYNCHEK2CHEK1BMPR1ATGFBR1 | |
| SCHEMBL1679739 | 0.86 | FYN (0.81) | FYNCHEK2CHEK1MKNK1 | |
| SCHEMBL1679092 | 0.83 | FYN (0.80) | FYNCHEK2CHEK1TGFBR1 | |
| SCHEMBL12734521 | 0.83 | FYN (0.77) | FYNCHEK2CHEK1MKNK1 | |
| SCHEMBL4622826 | 0.83 | FYN (0.70) | FYNBMPR1ATGFBR1ACVRL1ACVR1 | |
| SCHEMBL1678990 | 0.82 | FYN (0.69) | FYNATR | |
| SCHEMBL2224294 | 0.82 | FYN (0.72) | FYNCHEK2CHEK1MKNK1 | |
| SCHEMBL1678994 | 0.82 | FYN (0.75) | FYNCHEK2CHEK1 | |
| SCHEMBL3861503 | 0.81 | KAT6A (0.56) | FYNATRMKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-04-28 | — | — | US | claimed |
| EP-2114887-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | Cancer Research Technology Limited (GB) | 2009-11-11 | — | — | EP | claimed |
| WO-2008074997-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2008-06-26 | — | — | WO | claimed |
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| EP-2114887-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | Cancer Research Technology Limited (GB) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008074997-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008074997-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098325-A1 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS | PKD2, PKD1, BAZ2B | FYN 1665/4885CHEK2 587/4885CHEK1 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.